China
Africa
Explore chapters and articles related to this topic
Development of palliative medicine in the United Kingdom and Ireland
Published in Eduardo Bruera, Irene Higginson, Charles F von Gunten, Tatsuya Morita, Textbook of Palliative Medicine and Supportive Care, 2015
67c Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: A multicentre, randomized, double-blind, crossover, pilot study. Support Care Cancer 21: 129-137, 2013.
Sarcopenia in Lung Cancer: A Narrative Review
Published in Nutrition and Cancer, 2023
Uzair Jogiat, Zaharadeen Jimoh, Simon R. Turner, Vickie Baracos, Dean Eurich, Eric L. R. Bédard
Anamorelin is a selective ghrelin-receptor agonist that has been used for the treatment of cancer cachexia. The ROMANA 1 and ROMANA 2 were two well-designed phase III RCTs that randomized patients with advanced NSCLC to anamorelin or placebo, with the primary endpoint of median change in LBM and hand grip strength (HGS) over a 12 week period (90). Both trials demonstrated a significant increase in LBM, but not HGS. These findings are supported by a Japanese phase II RCT, which demonstrated an increase in LBM, Karnofsky Performance Scale, and quality of life indices, but not HGS, among patients with NSCLC treated with anamorelin (91).
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
Published in Expert Opinion on Pharmacotherapy, 2021
Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
Anamorelin has indeed shown a remarkable improvement in body weight in patients with cancer cachexia, as a consequence of fat and muscle mass accrual, and also ameliorated specific parameters related to anorexia. However, anamorelin has not been able to improve muscle strength and function parameters in these patients. A successful treatment for cancer cachexia, therefore, should tackle concomitantly all the three domains of the syndrome, including changes in body composition, impaired nutrition, and decreased physical function.
Current advancements in pharmacotherapy for cancer cachexia
Published in Expert Opinion on Pharmacotherapy, 2023
Guilherme Wesley Peixoto da Fonseca, Ryosuke Sato, Maria Janieire de Nazaré Nunes Alves, Stephan von Haehling
Currently, there is a multicenter, randomized, double-blind, placebo-controlled clinical trial in phase II (NCT04844970; Table 1) in patients with advanced pancreatic cancer that has been administering orally 100 mg of Anamorelin once daily. The intervention period will last for 25 weeks with changes in body weight as the primary outcome. This trial may shed light on the impact of Anamorelin in other cancer types once trials using Anamorelin in cancer have been predominantly applied to patients with NSCLC.